First Human Trial of Partial Epigenetic Reprogramming Reports Early Safety Data
Life Biosciences has reported initial data from a Phase 1 trial of ER-100, an AAV-delivered and doxycycline-controlled OSK reprogramming therapy for optic neuropathies. The treatment is injected into the eye, with OSK expression induced for eight weeks and prednisolone used to reduce immune reactions. The trial is evaluating safety, tolerability, and visual endpoints during the first 56 days.
Partial epigenetic reprogramming seeks to return youthful chemical marks on DNA and associated structures without erasing cell identity or creating tumor-prone pluripotent cells. Safe exposure differs by cell type, and delivery constraints push early work toward accessible tissues such as the retina and optic nerve.
ER-100 carries OCT4, SOX2 and KLF4 into eye cells via AAV; oral doxycycline turns expression on for 56 days, while a prednisolone taper aims to curb AAV-related inflammation. Among three participants, the regimen was tolerated to Day 56, with no serious safety events reported and preliminary visual-field improvements in two.
If the early safety signal holds, this approach could matter most to older adults facing progressive optic-nerve disease, including glaucoma and NAION, for whom vision loss can affect independence, mobility, and caregiving needs. Clinicians and regulators may see the doxycycline-controlled design as a test case for future reprogramming therapies. Any societal benefit may depend on larger trials confirming durability, visual benefit, and manageable immune risks; near-term impact may remain limited to research participants and specialist eye-care centers.